NCT00468585View on ClinicalTrials.gov

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Breast Cancer
Interventions
DRUG

Capecitabine

DRUG

Bevacizumab

Trial Locations (5)

10021

Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York

10591

Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow

11570

Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan-Kettering Cancer Center at Commack, Commack

07920

Memorial Sloan-Kettering at Basking Ridge, Basking Ridge

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00468585 - Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model | Biotech Hunter | Biotech Hunter